Stock Analiz

Compass Therapeutics, Inc. CMPX

Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026

$0.77Market cap $139M
Open the interactive analysis →

Compass Therapeutics, Inc. (CMPX) is a healthcare company listed in the US with a market value of about $139M.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -35%.

About Compass Therapeutics

Compass Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances). It was profitable in 0 of the last 7 years in our data. Its share count rose by 50% over three years (dilution for shareholders).

Score: 0.4 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B1.0
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-44.5%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-100.0%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-5808.8%
ROIC (5-yr avg.)-34.9%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 7 years

Fiscal year2025202420232022202120202019
Revenue$0$850000$0————
Net income-$66M-$49M-$42M-$39M-$82M-$30M-$35M
Free cash flow-$49M-$45M-$41M-$34M-$21M-$27M-$32M
EPS (diluted)$-0.42$-0.36$-0.33$-0.37$-1.31$-0.96$-5.19
Net margin—-5808.8%—————
ROIC-27.9%-33.9%-33.5%-22.6%-56.8%-44.6%-102.9%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Compass Therapeutics pay a dividend?

Not currently.

Is Compass Therapeutics a good stock to buy?

We do not give buy or sell advice. Compass Therapeutics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.